CD33 and hepatocellular carcinoma: The results revealed that HCC patients had a higher proportion of MDSCs compared to healthy controls, regardless of whether MDSCs were defined as “HLA-DRlow/−CD11b+CD33+” or “HLA-DRlow/-CD14+”, two most commonly used markers of MDSCs in HCC patients.